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ttp://dx.doi.org/10.1016/j.ajpath.2015.01.016Direct implantation of viable surgical specimens provides a representative preclinical platform in
pancreatic adenocarcinoma. Patient-derived xenografts consistently demonstrate retained tumor
morphology and genetic stability. However, the evolution of the tumor microenvironment over time
remains poorly characterized in these models. This work speciﬁcally addresses the recruitment and
incorporation of murine stromal elements into expanding patient-derived pancreatic adenocarcinoma
xenografts, establishing the integration of murine cells into networks of invading cancer cells. In
addition, we provide methods and observations in the establishment and maintenance of a patient-
derived pancreatic adenocarcinoma xenograft model. A total of 25 histologically conﬁrmed pancre-
atic adenocarcinoma specimens were implanted subcutaneously into nonobese diabetic severe
combined immunodeﬁciency mice. Patient demographics, staging, pathological analysis, and out-
comes were analyzed. After successful engraftment of tumors, histological and immunoﬂuorescence
analyses were performed on explanted tumors. Pancreatic adenocarcinoma specimens were suc-
cessfully engrafted in 15 (60%) of 25 attempts. Successful engraftment does not appear to correlate
with clinicopathologic factors or patient survival. Tumor morphology is conserved through multiple
passages, and tumors retain metastatic potential. Interestingly, despite morphological similarity
between passages, human stromal elements do not appear to expand with invading cancer cells.
Rather, desmoplastic murine stroma dominates the xenograft microenvironment after the initial
implantation. Recruitment of stromal elements in this manner to support and maintain tumor growth
represents a novel avenue for investigation into tumor-stromal interactions. (Am J Pathol 2015, 185:
1297e1303; http://dx.doi.org/10.1016/j.ajpath.2015.01.016)Supported by National Cancer Institute grant 5T32CA106493-09 and
Cracchiolo Foundation (S.J.H.).
Disclosures: None declared.A recent analysis of phase 1 cancer trials conducted from
2001 to 2012 revealed an overall objective response rate in
only 3.8% of patients.1 At some point, most agents included
in this analysis demonstrated efﬁcacy in xenograft models
derived from cancer cell lines. The poor predictive value of
cancer cell lines in vivo has been directly investigated and
largely attributed to genetic instability resulting from primary
culture.2,3 In contrast, patient-derived xenografts implant
viable sections of cancer tissue directly into an immuno-
compromised host, thus avoiding the cell culture processstigative Pathology.
.altogether. In addition, patient-derived xenotransplantation
demonstrates up to 10 times the success rate of cell line
derivation from cancer specimens.4,5 Therefore, patient-
derived xenografts represent a greater proportion of human
malignancies, demonstrate reliable genetic stability, and are
more predictive of clinical outcomes.6,7
Delitto et alIn particular, reliable preclinical models are desperately
needed in pancreatic cancer (PC). PC is the fourth leading
cause of cancer death in the United States, projected to be
second only to lung cancer by 2030.8 Cytotoxic chemo-
therapy represents the major treatment modality in 80% of
patients presenting with PC, extending survival to only 5 to
7 months,9,10 and the addition of recently approved targeted
therapies, such as erlotinib or nab-paclitaxel, only prolongs
survival by an estimated 1 to 2 months.11,12 Thus, annual
death rates from PC continue to increase, underlining a
global need for more representative preclinical models in the
development of novel therapies.13
Notably, a small series investigating patient-derived
xenografts in PC indicated a high degree of genetic stability
when compared to the original PC specimen.14 We sought to
expand on this method in a cohort of 23 patients with PC,
including two patients with metastatic lesions. Indeed, our re-
sults indicate that xenotransplantation of patient-derived PC
specimens into immunocompromised mice successfully
generated tumor grafts inmost cases. Patient-derived xenografts
retain morphological characteristics of the original PC spec-
imen as well as metastatic potential from the implantation site.
Furthermore, our results indicate that murine stroma is inte-
grated into networks of expanding PC cells. Implications from
this model are globally applicable to investigations into new
pharmacological agents against PC, speciﬁcally agents that
target tumor-stromal interactions.
Materials and Methods
Murine Xenograft Experiments
A viable 2  2-mm portion of tissue was immediately
isolated from a surgically resected primary PC specimen
with minimal ischemia time. PC tissue was then
implanted subcutaneously into an 8-week-old female
nonobese diabetic severe combined immunodeﬁciency
mouse (Jackson Laboratory, Bar Harbor, ME). Xenografts
were allowed to grow to a maximum diameter of 1.5 cm
before passage. Herein, we deﬁne a passage as explan-
tation of a PC xenograft and implantation into the ﬂank
of a new host. Tumor dimensions were measured three
times per week using calipers. Tumor volumes were
calculated using the following equation: v Z (xy)2/2,
where v is volume, x is tumor length, and y is tumor
width. Final growth rate was determined using the
amount of time taken to reach 1.5 cm in maximum
diameter. Histological analysis of specimens was per-
formed using hematoxylin and eosin staining.
Cells were isolated from the blood of tumor-bearing mice
by cardiac puncture and subjected to puriﬁcation using a
Ficoll Paque gradient (Sigma-Aldrich, St. Louis, MO). Live
cells were then cultured in RPMI 1640 medium, 10% fetal
calf serum, 20 ng/mL epithelial growth factor, and antibiotic
antimycotic solution (Sigma-Aldrich) for 2 months before
ﬁxation and staining.1298Patient Data and Statistical Analysis
A review of an institutional review boardeapproved, pro-
spectively maintained PC database at the University of
Florida (Gainesville) was performed. Clinicopathologic data
were analyzed for patients who underwent pancreatic resec-
tion for PC. All statistical analysis was performed using SPSS
version 22.0 (IBM SPSS Statistics for Windows; IBM Corp.,
Armonk, NY). All clinical data were tested for normality
using the Shapiro-Wilk test and displayed nonparametric
distributions (P < 0.05). U-tests and c2 coefﬁcients were,
therefore, used to determine signiﬁcance between groups
for continuous and categorical variables, respectively.
Kaplan-Meier survival curves and a Cox proportional haz-
ards model examined the respective effects of successful
engraftment and xenograft growth rate on overall survival.
The log-rank test was used to determine survival differences
between groups in Kaplan-Meier analysis. P < 0.05 was
considered statistically signiﬁcant.
Antibodies and Immunoﬂuorescence Analysis
Immunohistochemical staining of tissue specimens was
performed by the University of Florida’s Molecular Pathol-
ogy Core Facility. Brieﬂy, patient tumors, xenografts, and
murine organ specimens were analyzed in formalin-ﬁxed,
parafﬁn-embedded sections (5 mm thick). Hematoxylin and
eosin stains were performed on all specimens, and subse-
quent stains were performed in serial sections (5 mm thick).
Primary antibodies against human-speciﬁc vimentin and
human leukocyte antigen (HLA)-A (Abcam, Cambridge,
UK) were used after antigen retrieval with citrate buffer (pH
6.0) in tissue immunohistochemical analysis. Immunocyto-
chemistry was similarly performed after methanol ﬁxation of
cells in culture.
Results
Patient-Derived PC Xenografts Demonstrate Reliable
Growth Patterns in Immunocompromised Mice
In total, 15 (60%) of 25 patient-derived PC specimens were
successfully engrafted subcutaneously into nonobese dia-
betic severe combined immunodeﬁciency mice. Wounds
healed by postoperative day 7. Tumor invasion into muscular
tissue was typically observed by week 2, palpable growth
was observed by week 3, and growth end point (1.5 cm) was
reached within 8 to 16 weeks (Figure 1A). Because each
xenograft represents a speciﬁc patient, we hypothesized that
clinically signiﬁcant markers would correlate with successful
engraftment and subsequent growth kinetics. Interestingly,
all examined clinicopathologic parameters displayed no
correlation with successful engraftment or PC xenograft
growth rate (Tables 1 and 2 and Figure 1B). Accordingly,
neither successful engraftment nor growth rate correlated
with overall patient survival (Figure 1C). Although theajp.amjpathol.org - The American Journal of Pathology
Figure 1 Patient-derived pancreatic cancer (PC) xenografts demonstrate rapid growth on subcutaneous implantation into immunocompromised mice.
A: PC engraftment process is shown chronologically with representative histological correlates at the time of surgical resection and implantation (week 0),
weeks 1 through 3, and growth end point (week 8). The subcutaneous wound heals by week 1, and malignant invasion of murine tissues is present as early as
week 2. B: Clinicopathologic parameters do not correlate with xenograft growth rate. Tumor site, stage, grade, and neoadjuvant chemotherapy were
assessed for effects on xenograft growth rate (cm per month) among successfully engrafted PC specimens. Statistical comparisons were performed using the
Wilcoxon rank sum test. C: Successful engraftment does not correlate with patient survival. Patients were followed up after engraftment, and Kaplan-Meier
survival curves were generated (median  SEM). Patient survival was similar between both failed (dashed line) and successful (solid line) engraftment
groups (median overall survival, 7.6  0.6 versus 7.7  0.6 months; P Z 0.60). In addition, a Cox proportional hazards model reveals no correlation
between xenograft growth rate (cm/month) and survival (hazards ratio, 0.63; PZ 0.77). nZ 15 (B). Original magniﬁcation, 10 [hematoxylin and eosin
(H&E) images, A]. Scale bars: 300 mm (A).
Patient-Derived Xenografts in PCprecise conclusions from these data are limited, we speculate
that successful PC engraftment is likely dependent on tech-
nical, rather than patient, factors. Speciﬁcally, the reduction
of tumor ischemia time to an absolute minimum is critical to
successful engraftment.
Patient-Derived PC Xenografts Retain Tumor
Morphology and Metastatic Capacity in Murine Tissue
Patient-derived PC xenografts maintained architectural
characteristics of the original PC specimen after contin-
uous passaging. Our results demonstrated retention ofThe American Journal of Pathology - ajp.amjpathol.orgtumor morphology, speciﬁcally with regard to tumor dif-
ferentiation and glandular formation (Figure 2A). Des-
moplastic stromal elements persisted through multiple
passages of PC xenografts into new mice. We next asked
whether human tumor cells circulated systemically in mice
bearing patient-derived PC xenografts. To address this,
cells were isolated from the blood of tumor-bearing mice
and cultured. Subsequent immunoﬂuorescence analysis
revealed positive human HLA-A staining, indicating that
these circulating cells were of human origin (Figure 2B). In
addition, the metastatic potential of PC xenografts is
demonstrated in this model, which is similarly maintained1299
Table 1 Clinicopathologic Parameters Do Not Correlate with
Successful Tumor Engraftment
Parameter
Successful engraftment
P valueNo (n Z 10) Yes (n Z 15)
Age, years* 67.2  3.8 67.2  2.6 0.765
Tumor locationy
Pancreas 10 (100) 13 (87) 0.500
Hepatic metastasis 0 2 (13)
N1 stagey 8 (80) 11 (85) 1.00
Positive lymph node ratio* 0.22  0.07 0.14  0.03 0.522
Poor tumor differentiationy 4 (40) 6 (46) 1.00
Tumor size (cm)* 3.05  0.44 3.59  0.27 0.563
CA 19-9 (U/mL)* 1514  994 1437  775 0.546
Neoadjuvant therapyy 2 (20) 4 (31) 0.660
R1 resectiony 4 (40) 5 (39) 1.00
Clinicopathologic variables were assessed for effects on successful
pancreatic cancer engraftment using c2 coefﬁcients for categorical vari-
ables or the Wilcoxon rank sum test for continuous variables because of
nonparametric distributions.
*Data are given as means  SEM.
yData are given as number (percentage).
Table 2 Among Successfully Engrafted Tumors, Clinicopatho-
logic Parameters Do Not Correlate with Xenograft Growth Rate
Parameter Correlation (Spearman’s r) P value
Age (years) 0.254 0.362
Positive lymph node ratio 0.008 0.979
Tumor size (cm) 0.025 0.936
CA 19-9 (U/mL) 0.284 0.326
Age, positive lymph node ratio, tumor size, and preoperative CA 19-9
were compared with xenograft growth rate (cm/month growth in maximum
diameter) among successfully engrafted xenografts (n Z 15) using
Spearman’s rank order correlation.
Delitto et althrough multiple passages. We have observed hepatic,
pulmonary, and splenic metastases in mice bearing patient-
derived xenografts, conﬁrmed by hematoxylin and eosin
examination (Figure 2C). This model, therefore, in-
corporates desmoplastic architectural features generated
from tumor-associated stromal elements in the microen-
vironment. Furthermore, human cells originating in these
tumors circulate systemically and metastasis continues to
occur in murine tissue. More important, this phenomenon was
not observed in all patient-derived PC xenografts. Metastatic
patterns in murine tissue are displayed for xenografts derived
from six different patients with PC (Table 3). Subcutaneous
human PC tumors display a propensity to metastasize to
pulmonary tissue in immunosuppressed mice. However, our
preliminary observations demonstrate no speciﬁc correlation
between clinicopathologic parameters and metastasis in
murine tissue.
Murine Stromal Elements Are Incorporated into
Expanding Patient-Derived PC Xenografts
Tumor-stromal interactions in the microenvironment repre-
sent a current focus in PC. We, therefore, asked whether
stromal incorporation into expanding PC xenografts was of
human origin. To answer this question, we incorporated
immunohistochemical and immunoﬂuorescence staining
using human-speciﬁc antibodies. Each method reveals that
human stromal elements actively produce vimentin in PC
specimens (Figure 3, A and E). However, on incorporation
into a PC xenograft, a transition area is consistently observed
surrounding a 2-mm core of tissue representing the implanted
PC specimen. Positive staining for human-speciﬁc vimentin
diminishes in this area (Figure 3, BeD). Peripheral sampling
of a PC xenograft conﬁrms the presence of human HLA-A1300containing PC cells and the absence of human-speciﬁc
vimentin-positive stroma (Figure 3F). Taken together,
these results indicate that PC xenografts incorporate murine
stromal elements. Therefore, despite retention of tumor-
stromal morphology, stromal elements in continuously
passaged patient-derived PC xenografts are actually of
murine origin.
Discussion
We sought to examine the feasibility of patient-derived
PC xenotransplantation and its potential for wider appli-
cation in preclinical investigations. We describe initial
results with respect to patient-derived PC xenograft
morphology, metastatic ability, and incorporation of
murine cellular components. Our data indicate that these
xenografts are an effective method of investigating a
representative population of PC specimens. We demon-
strate that xenografts maintain the architecture of the
original tumor, particularly with respect to desmoplastic
elements that are common in PC. Remarkably, murine
stromal elements are incorporated into expanding xeno-
grafts, representing an important consideration for further
preclinical work with this model.
It is important to recognize that patient-derived xeno-
grafts have been extensively characterized in other models.
In fact, success rates of up to 70% to 100% have been
reported in multiple series.4,5,14 This leads us to conclude
that successful engraftment in PC is likely more dependent
on technical, rather than clinicopathologic, factors,
particularly the reduction of ischemia time to an absolute
minimum. Regarding PC, replacement of human stroma
has been suggested by species-speciﬁc genomic ana-
lyses.7,15 This work demonstrates the replacement of
human stroma by murine elements, because these elements
are mostly undetectable beyond the original implanted
specimen. Interestingly, desmoplastic elements are
retained in continuously passaged xenografts, indicating
that an important component of tumor-stromal interactions
may not be species speciﬁc.
Our work contrasts with the work of other groups in
that we demonstrate metastatic potential from subcu-
taneous patient-derived xenografts.4,16 It is important toajp.amjpathol.org - The American Journal of Pathology
Figure 2 Patient-derived pancreatic cancer (PC) xenografts retain tumor morphology and metastatic ability. A: Hematoxylin and eosin (H&E) analysis of
six separate PC specimens and corresponding patient-derived xenografts reveals maintenance of tumor differentiation and perpetuation of the desmoplastic
tumor microenvironment. Notably, tumors maintain their differentiation on engraftment and passage in mice. B: Human cells circulate in the blood of mice
bearing patient-derived PC xenografts. Immunoﬂuorescence analysis of cells isolated from the blood of tumor-bearing mice and cultured cells reveals the
expression of human leukocyte antigen-A (green), indicating the human origin of cultured cells. Nuclei are stained with DAPI (blue). C: A subcutaneous,
patient-derived, PC xenograft was explanted after 2 months of growth. Postmortem laparotomy and thoracotomy reveal gross metastatic disease to the liver,
lungs, and spleen. Tumor metastasis was conﬁrmed by H&E analysis. Arrows indicate metastatic foci. Original magniﬁcations: 20 (H&E images, A); 10 (C).
Scale bars: 200 mm (A); 300 mm (C).
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Table 3 Metastatic Patterns of Patient-Derived PC Xenografts from Six Patients
Patient no. Stage Differentiation Neoadjuvant chemotherapy Overall survival (months) Metastatic sites in mouse
1 T3N0M0 Moderate to poor No 7.6 None
2 T3N1M0 Moderate No Alive at 15 months None
3 T3N1M0 Moderate to poor No 4.1 None
4 T3N1M0 Poor No 2.4 Lungs
5 T3N1M0 Moderate Yes Alive at 7 months Lungs, liver, and spleen
6 T3N1M1 Poor No 7.9 Lungs
Xenografts from six different patients were examined for metastatic patterns. Organs were harvested from mice bearing tumors at size end points and
analyzed via hematoxylin and eosin examination. Clinicopathologic characteristics of each patient are displayed as well as metastatic patterns of xenografts.
PC, pancreatic cancer.
Delitto et alrecognize that these cases typically displayed direct in-
vasion into musculoskeletal tissue. However, we have
observed systemically circulating human cells and meta-
static spread to multiple intra-abdominal organs in the
absence of peritoneal extension of the primary tumor.
Notably, subcutaneous xenografts have been widely crit-
icized due to a lack of observed metastatic potential.
However, in contrast to direct orthotopic implantation into
the murine pancreas, subcutaneous xenografts provide
major advantages with respect to the technical expertise
required and ease of monitoring, enabling a wider1302application and higher throughput. Our ﬁndings reinforce
the validity of subcutaneous xenografts as a preclinical
model.
In summary, we demonstrate that the generation of a
patient-derived PC xenograft model is feasible with a high
rate of successful engraftment. We additionally reveal two
important considerations for future preclinical investigations.
First, murine stromal elements are incorporated into
expanding xenografts early after implantation. Second, PC
xenografts demonstrate metastatic potential from implanta-
tion sites. These ﬁndings support the investigations ofFigure 3 Murine stromal elements are incor-
porated into expanding patient-derived pancreatic
cancer (PC) xenografts. A: Immunoperoxidase
staining for human-speciﬁc vimentin demonstrates
diffuse stromal staining in a representative human
PC specimen. B: The resultant PC xenograft reveals
conserved human stroma in the original 2-mm core
of tissue representing the implanted human PC
specimen. Human-speciﬁc vimentin staining di-
minishes signiﬁcantly beyond the initial xenograft
invasion front (black dotted line). C: Hematoxylin
and eosin staining of a separate patient-derived
xenograft demonstrates continued desmoplasia at
the invasion front (white dotted line). D: A serial
section stained for human vimentin (green) again
demonstrates relatively few human stromal cells
beyond the initial invasion front (white dotted
line). E: Similarly, dual immunoﬂuorescence
staining for human-speciﬁc vimentin (green) and
human leukocyte antigen (HLA)-A (red) demon-
strates diffuse HLA-A staining and stromal-speciﬁc
human vimentin staining in a PC specimen. F:
Conversely, peripheral sampling of the corre-
sponding PC xenograft reveals human cancer cells
displaying HLA-A and undetectable human-speciﬁc
vimentin staining. Single asterisks indicate orig-
inal PC implants; double asterisks, invasive fronts
of implanted PC specimens. Scale bar: 300 mm (C).
ajp.amjpathol.org - The American Journal of Pathology
Patient-Derived Xenografts in PCestablishing patient-derived tumor xenografts as an emerging
preclinical model in PC.
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